Related references
Note: Only part of the references are listed.Infectious Complications and Hospital Admissions After Prostate Biopsy in a European Randomized Trial
Stacy Loeb et al.
EUROPEAN UROLOGY (2012)
Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008
Willi Oberaigner et al.
INTERNATIONAL JOURNAL OF PUBLIC HEALTH (2012)
Screening for Prostate Cancer: A Review of the Evidence for the US Preventive Services Task Force
Roger Chou et al.
ANNALS OF INTERNAL MEDICINE (2011)
Screening for prostate cancer: an updated Cochrane systematic review
Dragan Ilic et al.
BJU INTERNATIONAL (2011)
What Is the True Number Needed to Screen and Treat to Save a Life With Prostate-Specific Antigen Testing?
Stacy Loeb et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
American Cancer Society Guideline for the Early Detection of Prostate Cancer Update 2010
Andrew M. D. Wolf et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
Estimates of cancer incidence and mortality in Europe in 2008
J. Ferlay et al.
EUROPEAN JOURNAL OF CANCER (2010)
A Risk-Based Strategy Improves Prostate-Specific Antigen-Driven Detection of Prostate Cancer
Monique J. Roobol et al.
EUROPEAN UROLOGY (2010)
Mortality results from the Goteborg randomised population-based prostate-cancer screening trial
Jonas Hugosson et al.
LANCET ONCOLOGY (2010)
Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials
Mia Djulbegovic et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
15-Year Followup of a Population Based Prostate Cancer Screening Study
Anders Kiellman et al.
JOURNAL OF UROLOGY (2009)
Mortality Results from a Randomized Prostate-Cancer Screening Trial
Gerald L. Andriole et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Screening and Prostate-Cancer Mortality in a Randomized European Study
Fritz H. Schroeder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial
Robert L. Grubb et al.
BJU INTERNATIONAL (2008)
Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/mL or lower
IM Thompson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Clinical consequences of screening for prostate cancer:: 15 years follow-up of a randomised controlled trial in Sweden
G Sandblom et al.
EUROPEAN UROLOGY (2004)
Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter
IM Thompson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Screening decreases prostate cancer mortality:: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial
F Labrie et al.
PROSTATE (2004)
Lead times and overdetection due to prostate-specific antigen screening:: Estimates from the European randomized study of screening for prostate cancer
G Draisma et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program
R Raaijmakers et al.
UROLOGY (2002)
Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria
G Bartsch et al.
UROLOGY (2001)
Share Paper
